Yasuhiro Torikoshi

Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer

S.J. Kim, Satoshi Nakayama, Yasuo Miyoshi et al. · Annals of Oncology · 2007 · 102 citations · Full text

Medicine, Cell Biology, Oncology +11

High expression of <i>ubiquitin carboxy‐terminal hydrolase‐L1</i> and <i>‐L3</i> mRNA predicts early recurrence in patients with invasive breast cancer

Yasuo Miyoshi, Satoshi Nakayama, Yasuhiro Torikoshi et al. · Cancer Science · 2006 · 92 citations · Full text

Life Sciences, Molecular Biology, Oncology +15

Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells

Satoshi Nakayama, Yasuhiro Torikoshi, Takeshi Takahashi et al. · Breast Cancer Research · 2009 · 88 citations · Full text

Life Sciences, Cancer Biology, Pharmacology +17

Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers

S.J. Kim, Satoshi Nakayama, Kenzo Shimazu et al. · Annals of Oncology · 2011 · 26 citations · Full text

Medicine, Oncology, Pharmacology +14

A new cancer diagnostic system based on a CDK profiling technology

Hideki Ishihara, Tomokazu Yoshida, Yuko Kawasaki et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2005 · 24 citations

Medicine, Cancer Biology, Oncology +14